• Paxman secured first UK orders for four neuropathy systems from a private cancer care provider within a major international healthcare group.
• The systems will be installed at four UK locations in December 2026, marking the product's first commercial installations in the country.
• The orders mark the company's first expansion beyond scalp cooling into managing chemotherapy-induced peripheral neuropathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paxman AB published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.